🚨Discover the latest addition to our resources – the NEW LiVDerm Clinician Diagnosis Guide tailored specifically for psoriasis in patients with #SkinOfColor! 🔗go.livderm.org/3zDOcxW

Did you know that women are significantly underrepresented in clinical trials, research, and studies? This gap in representation underscores the critical need for focused women's health education. ➡ Meet our incredible faculty and what they will be discussing at the Women's

Interested in learning more about diagnosing and treating psoriasis in patients with skin of color? Check out the Skin of Color Resources for Health Care Providers from National Psoriasis Foundation 🔗Take a look: go.livderm.org/3xOWtPe #LiVDerm #Psoriasis #SkinOfColor

Early results from the Determi-Nation Patient Navigator Program: 👨‍⚕️ Insurance and pharmacy support 📆 Appointment reminders and assistance 🏥 Patient resources for diagnosis, treatment, and health literacy 💡 And more! J&J Innovative Medicine 🔗 go.livderm.org/3WoRwG5

July is UV Safety Month: A crucial opportunity to reinforce patient education on photoprotection. ☀️Dermatologists play a key role in emphasizing the multifaceted approach to preventing UV-induced skin damage, photoaging, and cutaneous malignancies. #UVSafetyMonth #SunSafety

💟 Fatima Cody Stanford MD MPH MPA MBA FAAP FACP FAHA is excited to welcome you to the upcoming Women's Health Summit! 🚨 Don't miss this exclusive event! 🔗 cmhc.info/3RDpqnT This fall, Informa Connect's Medical Division has curated an incredible curriculum specifically designed to address the critical gaps

☀️#UVSafetyMonth Spotlight: DART's New Clinical Guidelines The Dermatology Association of Radiation Therapy (DART) unveils comprehensive guidelines for BCC and SCC management. Continue reading about the latest updates here: go.livderm.org/3WI6d7k Source: Dermatology Times

We are thrilled to announce that the fourth episode of our new podcast series which focuses on #JAKInhibitors for #AtopicDermatitis (AD) is now available. 🎧 Listen now: go.livderm.org/3WUGUz1 Ruth Ann Vleugels, MD, MPH, MBA #DermDocs #Podcast #DermTwitter

Don't miss out on our Olympic-sized savings! 🌟 Just as Olympic athletes strive for gold, we’re offering you a golden opportunity to immerse yourself in the latest advancements in women’s healthcare. ➡️ Use code ⭐GOGOLD: go.livderm.org/4djLJrl #WomensHealthSummit #Dermatology

✨ Check out the first episode of a two-part activity on Skirting Steroids in Atopic Dermatitis, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD & Peter Lio, MD 🚨 Watch the full podcast: go.livderm.org/3YH4FMk #LiVDerm #DermDocs #Dermatology

🚨 Did you know? Experts including the International Eczema Council (IEC) and AAD (AAD) guidelines recommend against the use of systemic corticosteroids. 🔗 go.livderm.org/47bT5ex #Dermatology #AtopicDermatitis

❓ Do you know what topical corticosteroid abuse looks like? The typical features of topical steroid overuse and withdrawal include burning, stinging, and bright red skin that occur with days to weeks of discontinuation.  🔗 go.livderm.org/3T1SfLh Source: National Eczema

🧬 Despite patient reports of acne vulgaris linked to GLP-1 receptor agonist use on social media, no strong evidence supports this association, possibly due to recent popularity and lack of specific dermatologic studies. #dermtwitter dermatologytimes.com/view/glp-1-ago…

Pumpkin Spice in August? We see your early hype and raise you SBS 2025! 🌴 The South Beach Symposium is heading back to the beach for its 23rd year of pioneering dermatology evolution. And we’re just getting started. Explore details + reserve your spot: go.livderm.org/3T36EqA

ICYMI: The U.S. FDA Approved Roflumilast Cream 0.15% for the Treatment of AD in Adults and Children Down to 6 Years of Age Treatment with roflumilast rapidly and significantly reduced itch, the most bothersome symptom of AD 🔗 Read more: go.livderm.org/3T9g9of

ICYMI: Recent 52-week results from a maximum-use trial of ruxolitinib in children aged 2-11 years with extensive, moderate to severe AD found that at 4 and 52 weeks, 53.8% of subjects achieved IGA–Treatment Success 🔗 Read more: go.livderm.org/3T7zyG6

Recently published data from the phase 3 CrisADe CONTROL trial assessing crisaborole in mild to moderate AD demonstrated long-term efficacy with a 111-day median duration of flare-free maintenance vs a 30-day duration in those treated with vehicle 🔗go.livderm.org/4gdB6rZ #Derm

Tapinarof is a topical aryl hydrocarbon receptor agonist that is under investigation in adults + adolescents with AD of all severities. It demonstrated significant efficacy and favorable safety & tolerability in a diverse population of patients aged 2+.🔗 go.livderm.org/3XeZBfJ

Topical corticosteroids work similarly across skin colors, but high-potency ones can cause hypopigmentation in darker skin. Pimecrolimus cream 1% and crisaborole have shown effective results and improvements in AD for Black and Hispanic populations.

Atopic dermatitis (AD) may lead to long-term corticosteroid use and higher side effect risks. 83% of adults and 64% of children using prescription corticosteroids report worsening symptoms over time. Explore corticosteroid-sparing strategies. 🔗go.livderm.org/3XD94z0